Skip to main content

Table 4 Effect of PHCSBD on haematological parameters

From: Evaluation of anti-malarial potency of new pyrazole-hydrazine coupled to Schiff base derivatives

Treatment Dose (mg/kg) Parasitaemia count
RBC (106/μL) WBC (103/μL) PCV (%) HB (g/dl)
Control 5.16 ± 3.88 8.22 ± 1..76 19.50 ± 1.59 5.75 ± 0.96
BePINH 2.5 9.81 ± 1.96 9.77 ± 1.37 38.25 ± 0.83* 10.63 ± 0.19*
10 10.63 ± 1.28* 10.57 ± 2.02 36.50 ± 1.10* 11.03 ± 0.39*
15 10.86 ± 1.11* 10.92 ± 1.70 37.25 ± 0.96* 12.18 ± 0.19*
BePBeH 2.5 8.24 ± 2.92 9.55 ± 1.56 36.87 ± 1.21* 10.71 ± 0.74*
10 9.89 ± 1.31 10.41 ± 1.24 37.02 ± 0.92* 10.87 ± 0.81*
15 10.31 ± 0.29* 10.85 ± 0.82 37.53 ± 1.01* 11.17 ± 1.25*
ACT 5 10.99 ± 1.17* 10.60 ± 1.70 41.50 ± 1.70* 12.00 ± 0.32*
  1. Each value represents the mean ± S.E.M, n = 5
  2. ACT Artemisinin-based Combination Therapy, RBC red blood cells, WBC white blood cells, PCV packed cell volume, HB haemoglobin
  3. *p < 0.05 compared with control (One-way ANOVA; Dunnett’s post hoc)